SCHEMBL20393293

SCHEMBL20393293

NS(=O)(=O)c1ccc(N2CCN(C3CCCCC3)C2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 10/20 0.51
CA2 P00918 10/20 0.51
CA9 Q16790 9/20 0.51
CA12 O43570 8/20 0.51
CA7 P43166 4/20 0.51
CA5B Q9Y2D0 4/20 0.51
CA5A P35218 3/20 0.51
CA4 P22748 3/20 0.51
CA6 P23280 3/20 0.51
CA14 Q9ULX7 3/20 0.51
CA13 Q8N1Q1 2/20 0.51
PTGS2 P35354 1/20 0.45
MT-CO2 P00403 2/20 0.43
ALOX5 P09917 2/20 0.43
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CTSG P08311 1/20 0.40
CMA1 P23946 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18361724 0.99 CA12 (0.52) CA1CA2CA9CA12CA7
SCHEMBL18361705 0.73 CA1 (0.74) CA1CA2CA9CA12CA7
SCHEMBL18361704 0.73 CA1 (0.60) CA1CA2CA9CA12CA7
SCHEMBL8413926 0.73 KHK (0.45)
SCHEMBL28543449 0.73 DPP4 (0.60) CA1CA2CA9CA12CA7
SCHEMBL14549757 0.73 DPP4 (0.60) CA1CA2CA9CA12CA7
SCHEMBL18361665 0.72 CA1 (0.48) CA1CA2CA9CA12CA7
SCHEMBL18361587 0.71 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL31662436 0.71 F10 (0.43) TDP1
SCHEMBL18361706 0.70 CA2 (0.58) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922345-B Arylsulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use 圣诺康生命科学公司 2021-03-23 CN claimed
CN-107922345-B Arylsulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use 圣诺康生命科学公司 2021-03-23 CN disclosed
US-10562859-B2 Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use SIGNALCHEM LIFESCIENCES CORPORATION (CA) 2020-02-18 US disclosed
US-20180201584-A1 ARYL SULFONAMIDE COMPOUNDS AS CARBONIC ANHYDRASE INHIBITORS AND THEIR THERAPEUTIC USE SIGNALCHEM LIFESCIENCES CORPORATION (CA) 2018-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562859-B2 Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use CA9, CA4, CA7 CA1 8/4885CA2 5/4885CA9 1/4885
US-20180201584-A1 ARYL SULFONAMIDE COMPOUNDS AS CARBONIC ANHYDRASE INHIBITORS AND THEIR THERAPEUTIC USE CA9, CA4, CA7 CA1 8/4885CA2 5/4885CA9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.